Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ira Jacobs

Showing results (51-60 of 82) with videos related to

Pageof 9
Sort By:
Rheumatology International|February 28, 2016
Clinical and regulatory perspectives on biosimilar therapies and intended copies of biologics in rheumatologyEduardo Mysler, Carlos Pineda, Takahiko Horiuchi, et al.
International Journal of Sports Physiology and Performance|March 4, 2021
Menthol Mouth Rinsing and Cycling Performance in Females Under Heat StressErica H Gavel, Heather M Logan-Sprenger, Joshua Good, et al.
The Oncologist|December 8, 2017
The Role of Rituximab in Chronic Lymphocytic Leukemia Treatment and the Potential Utility of BiosimilarsJennifer R Brown, Florence Cymbalista, Jeff Sharman, et al.
Military Medicine|June 12, 2021
Dietary Intakes From Ad Libitum Consumption of Canadian Armed Forces Field Rations Compared With Usual Home Dietary Intakes and Military Dietary Reference IntakesMavra Ahmed, Iva Mandic, Wendy Lou, et al.
Future Oncology (London, England)|January 21, 2021
Addressing resistance to immune checkpoint inhibitor therapy: an urgent unmet needSiwen Hu-Lieskovan, Gabriel G Malouf, Ira Jacobs, et al.
European Journal of Applied Physiology|April 2, 2013
Role of exercise duration on metabolic adaptations in working muscle to short-term moderate-to-heavy aerobic-based cycle trainingHoward J Green, Margaret Burnett, Sherry Carter, et al.
Journal for Immunotherapy of Cancer|November 29, 2019
Peripheral immune-based biomarkers in cancer immunotherapy: can we realize their predictive potential?Andrew B Nixon, Kurt A Schalper, Ira Jacobs, et al.
British Journal of Cancer|July 14, 2018
Neoadjuvant PF-05280014 (a potential trastuzumab biosimilar) versus trastuzumab for operable HER2+ breast cancerPhilip E Lammers, Magdolna Dank, Riccardo Masetti, et al.
Future Oncology (London, England)|April 26, 2018
Bevacizumab biosimilars: scientific justification for extrapolation of indicationsBarbara Melosky, David A Reardon, Andrew B Nixon, et al.
Frontiers in Oncology|January 24, 2022
Application of Real-World Data to External Control Groups in Oncology Clinical Trial Drug DevelopmentTimothy A Yap, Ira Jacobs, Elodie Baumfeld Andre, et al.
Pageof 9

Showing results (51-60 of 82) with videos related to

Sort By:
Pageof 9
Rheumatology International|February 28, 2016
Clinical and regulatory perspectives on biosimilar therapies and intended copies of biologics in rheumatologyEduardo Mysler, Carlos Pineda, Takahiko Horiuchi, et al.
International Journal of Sports Physiology and Performance|March 4, 2021
Menthol Mouth Rinsing and Cycling Performance in Females Under Heat StressErica H Gavel, Heather M Logan-Sprenger, Joshua Good, et al.
The Oncologist|December 8, 2017
The Role of Rituximab in Chronic Lymphocytic Leukemia Treatment and the Potential Utility of BiosimilarsJennifer R Brown, Florence Cymbalista, Jeff Sharman, et al.
Military Medicine|June 12, 2021
Dietary Intakes From Ad Libitum Consumption of Canadian Armed Forces Field Rations Compared With Usual Home Dietary Intakes and Military Dietary Reference IntakesMavra Ahmed, Iva Mandic, Wendy Lou, et al.
Future Oncology (London, England)|January 21, 2021
Addressing resistance to immune checkpoint inhibitor therapy: an urgent unmet needSiwen Hu-Lieskovan, Gabriel G Malouf, Ira Jacobs, et al.
European Journal of Applied Physiology|April 2, 2013
Role of exercise duration on metabolic adaptations in working muscle to short-term moderate-to-heavy aerobic-based cycle trainingHoward J Green, Margaret Burnett, Sherry Carter, et al.
Journal for Immunotherapy of Cancer|November 29, 2019
Peripheral immune-based biomarkers in cancer immunotherapy: can we realize their predictive potential?Andrew B Nixon, Kurt A Schalper, Ira Jacobs, et al.
British Journal of Cancer|July 14, 2018
Neoadjuvant PF-05280014 (a potential trastuzumab biosimilar) versus trastuzumab for operable HER2+ breast cancerPhilip E Lammers, Magdolna Dank, Riccardo Masetti, et al.
Future Oncology (London, England)|April 26, 2018
Bevacizumab biosimilars: scientific justification for extrapolation of indicationsBarbara Melosky, David A Reardon, Andrew B Nixon, et al.
Frontiers in Oncology|January 24, 2022
Application of Real-World Data to External Control Groups in Oncology Clinical Trial Drug DevelopmentTimothy A Yap, Ira Jacobs, Elodie Baumfeld Andre, et al.
Pageof 9